ABSTRACT -Less than 1 % of the lung cancer cases from the Surveillance, Epidemiology, and End Results (SEER) Program changed categories as a result of the World Health Organization's revision of histologic classifications of lung tumors. Of the 28,119 microscopically proved lung cancers reported to SEER in 1977-79, 32% were squamous cell carcinoma, 16% were small cell and/or oat cell carcinoma, 27% were adenocarcinoma, 8% were large cell carcinoma, and 5% were other specified types. A further 12% (","3,500 cases) were reported with such nonspecific terms as bronchogenic carcinoma, carcinoma of the lung, and undifferentiated or anaplastic carcinoma. The magnitude of the use of these nonspecific terms showed the need for greater precision in reporting and recording data. -JNCI 1983; 70:663-666. The lung is one of the main sites where the histologic classification of cancer is important because of the relation between etiologic, pathologic, clinical, therapeutic, and prognostic features and the different histologic types of lung cancer. Thus studies on causation, diagnosis, and treatment of specific histologic types of lung cancer are more meaningful than studies that concern just the broad group cancer of the lung.
The lung is one of the main sites where the histologic classification of cancer is important because of the relation between etiologic, pathologic, clinical, therapeutic, and prognostic features and the different histologic types of lung cancer. Thus studies on causation, diagnosis, and treatment of specific histologic types of lung cancer are more meaningful than studies that concern just the broad group cancer of the lung.
The importance of histologic typing of lung tumors was underlined by the fact that the lung was selected as the first site to be covered by the WHO's IHCT Program (/). The result was the publication in 1967 of the first of the WHO "blue books," Histological Typing of Lung Tumours (2) . In terms of literature citations, this publication has been the most widely used of the 25 volumes that comprise the WHO series (I).
Recently, for update of this histologic classification of lung cancer, several WHO meetings were held, which resulted in a revised or second edition of the lung tumor classification (3) . One of the objects of this study was the application of the same data set to both the original and the revised WHO lung tumor classifications.
In the present study, over 28,000 lung cancer cases taken from the NCI's SEER Program (4) were categorized both by the original and by the revised WHO lung tumor classification 1) to see how a large data set such as SEER, which includes reports from a cross section of pathologists, fits into this internationally acceptable format and 2) to compare the original and revised WHO lung tumor classifications for determination of what effects the nosologic changes made in the revised classification had on the data.
MATERIALS AND METHODS
The SEER Program is a major undertaking by the NCI to compile data on the incidence of cancer in the United States and to follow these cases for the study of end results.
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Only malignant tumors and carcinomas in situ are collected. The program started in 1973 and by 1975 included 10 areas of the United States: 5 states, 4 metropolitan areas, and Puerto Rico, comprising about 10% of the U.S. population. The lung cancer cases used in this study came from all these areas. Ninety percent of the lung cancer cases collected by SEER and all those included in this study were diagnosed microscopically. They were not microscopically reviewed especially for this report. The other 10% of the lung cancer cases, which were excluded, were only diagnosed clinically or by radiography. SEER's information was gathered from hospital records and pathology reports, including autopsy records, surgical pathology, and cytologic examination of sputums. Each tumor diagnosis was abstracted and then coded for site and type by the ICD-O (5). ICD-O is a coded nomenclature and is a supplement to chapter II ("Neoplasms") of the ninth revision (9th ed.) of the International Classification of Diseases (ICD-9) (6). ICD-O provides not only a code for topography and histology of neoplasms but also indicates the behavior and grading or differentiation of tumors. It includes codes for all neoplastic terms from many classifications, but a particular effort was made to stress the histologic terms listed in the WHO's IHCT series (blue books), where criteria and definitions are given for the terms. Both in the IHCT and ICD-O, nonneoplastic lesions are coded by the SNOMED (7), which also includes in its morphology section the identical codes for neoplasms found in ICD-O. 
RESULTS
During the period 1977-79,28,119 cases of cancers of the lung and pleura that were microscopically confirmed were reported to the SEER Program. Of these cases 10% were from cytologic specimens, and the remaining 90% were from biopsies, surgical specimens, or autopsies. Although these cases were tabulated both by the original WHO lung tumor classification (1967) (2) and the revised classification (1981) (3) , only data derived from the revised classification are presented here (table 1) because less than 1 % of the cases changed categories.
The following are some of the changes in the revised classification compared to those of the original classification: 1) Benign epithelial tumors, dysplasia, and carcinoma in situ were added to the revised WHO classification (sections IA and B) (3) . Because SEER does not collect benign tumors, figures are not available (NA in table 1). 2) The rubric for papillary epidermoid carcinomas of surface epithelium (10 cases in this SEER data) was transferred to squamous cell carcinoma (I.C.1) in the Second Edition (3).
3) The subtypes of small cell carcinoma were reduced from 4 to 3 groups, but the total number of cases in this rubric was unchanged. In the revised WHO classification, oat cell carcinoma is a subtype of small cell carcinoma. We have given the figures for each as reported to SEER. 4) The category for large cell carcinoma with mucin-like content was transferred from the large cell category in the original classification to a subtype of adenocarcinoma-solid carcinoma with mucus formation (I.C.3.d.). Only 1 case was reported with this diagnosis. 5) Section VII, tumor-like lesions, was expanded in the revised classification.
The microscopically proved lung cancers collected for a 3-year period, 1977-79, are shown in table 1. They were coded by ICD-O/SNOMED and classified by the 1981 revised WHO histologic classification (3). The major categories of carcinoma, namely, squamous cell, small (oat) cell, large cell, and adenocarcinoma, were unchanged and therefore had virtually the same contents in both the original (2) and revised classifications (3), namely, squamous cell carcinoma, 32%; small (oat) cell carcinoma, 16%; adenocarcinoma, 27%; and large cell carcinoma, 8%, comprising 83% of the malignant tumors of the lung.
Five percent were other specified types, e.g., mesothelioma and carcinoid tumor. The remaining 12.5% of lung cancers were diagnosed only as carcinoma, NOS; bronchogenic carcinoma; undifferentiated carcinoma; or anaplastic carcinoma. No place was at all suitable in the 1967 classification for these 3,500 cases of insufficiently specified carcinomas. A category in the revised classfication-malignant epithelial tumors, others (I.C.8.)-accommodates them.
Some terms were used by pathologists, whose cases were reported to SEER, which were not specifically listed in either WHO classification (2, 3). For example, mucin-producing and mucinous carcinomas were reported for 2% of the cases. These categories are not specified in the WHO classifications because such forms may occur in any of the subtypes of adenocarcinoma. In table 1 
DISCUSSION
Modifications made in the revision (3) of the WHO lung tumor classification have not led to appreciable changes in frequencies in the distribution of cases. Less than 1 % of the total cases changed categories as a result of the revision of the classification. The major categories of lung cancer contain nearly the same proportion of cases in each version. The reason for this is that the changes affect 1) relatively uncommon tumors, e.g., papillary squamous cell carcinoma; 2) infrequently used di.agnoses, e.g., large cell carcinoma with mucus formation; and 3) subcategories without alteration of the major categories, namely, the subtypes of small cell carcinoma. Therefore, data tabulated by the original classification (2) can be readily compared to data tabulated by the revision (3), and time trends of histologic types of lung cancer can be easily studied without undue conversion problems.
Certainly, a disturbing finding of this study is the frequent use of terms of low specificity, namely, bronchogenic carcinoma; carcinoma, NOS; undifferentiated carcinoma; and anaplastic carcinoma. This finding correlates with an earlier study (9) showing that 19 of 57 (33%) published reports on lung cancer used undifferentiated or anaplastic carcinoma instead of specifying between large cell and small cell carcinomas. Although undifferentiated carcinoma and anaplastic carcinoma can have specific meanings at other tumor sites, e.g., the thyroid gland, their application to lung tumors lacks specificity because both terms can be applied to small cell and large cell carcinomas; therefore, the distinction is lost between these two very different tumor types. An even greater loss of specificity occurs by the use of the terms "bronchogenic carcinoma" and "carcinoma of the lung." Over 2,000 cases (8% of the total) were reported in this way. These diagnoses give no information on the actual histologic type. The lack of specific categories in the WHO classification for these unspecified terms was intended to discourage their use. An "unclassified tumor" category is provided in all WHO histologic classifications but is for cases in which the basic tissue component, e.g., epithelial versus connective tissue, is unrecognizable, i.e., the distinction between carcinoma and sarcoma. However, in view of many nonspecific carcinoma diagnoses, a separate category, e.g., unclassified carcinoma, would have been useful for the tabulation of lung tumors.
It is unlikely that terms such as bronchogenic carcinoma were used because of the inability of the pathologist to render a specific diagnosis. One explanation is that the specific tumor type was given in the pathologist's microscopic description, but a less specific term was used for the final diagnosis, which is the one coded. Several subtypes in the classification contain very few cases: 88% of the diagnoses were included in less than 10 categories; the remaining 12% were distributed in the other 28 categories of lung cancer. This situation raises the question of whether such a finely split classification is justified. In favor of splitting is the need for component pathology types to be defined, however rare. Furthermore, subdivided categories are easily grouped according to the needs of the study and to the sample size. In practice most reports on lung tumors, in which the WHO classification is used, group the tumors into the four major rubrics: squamous cell, small (oat) cell, and large cell carcinomas and adenocarcinoma. If a standardized classification is not subdivided at the outset, consistent subtyping is not readily achieved.
Classification is intended to promote order and to facilitate comparisons. This study has shown that the conservative revision of the WHO lung tumor classification has resulted in a minimum of conversion problems. It has also shown that despite efforts for standardization of classification and for development of an acceptable nomenclature, many lung cancer cases are still reported with insufficiently specific terms, thus not permitting meaningful interpretation.
